Published by Josh White on 18th October 2021
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said on Monday that a major US hospital-based clinical trial lent "strong support" for the potential of its 'XF-73' nasal product as an alternative to mupirocin in the treatment of Staphylococcus aureus infections.